Print

Sanofi (France) (SAN.PA)'s Gaucher Pill Meets Goal in Phase 3 Trial  
10/2/2012 7:49:23 AM

Sanofi's experimental pill to treat Gaucher disease, a rare inherited condition, has met its main goal in a late-stage trial, the French drugmaker said on Tuesday. Patients treated with the drug, eliglustat tartrate, showed a statistically significant improvement in the size of their spleen after nine months compared with those who took a placebo, Sanofi said in a statement. The treatment was well tolerated and showed no serious side effects during the trial, it said. Gaucher disease is a rare genetic disorder affecting some 10,000 patients worldwide. Patients with the disease are deficient in an enzyme that breaks down a certain type of fat, leading to potentially life-threatening organ damage and bone problems.
//-->